Androgen deprivation therapy and overall survival for Gleason 8 versus Gleason 9-10 prostate cancer.

Authors

null

David Dewei Yang

Harvard Medical School, Boston, MA

David Dewei Yang , Brandon Arvin Virgil Mahal , Vinayak Muralidhar , Neil E. Martin , Peter F. Orio , Kent William Mouw , Martin T. King , Toni K. Choueiri , Quoc-Dien Trinh , Karen E. Hoffman , Daniel Eidelberg Spratt , Felix Y Feng , Paul L. Nguyen

Organizations

Harvard Medical School, Boston, MA, Brigham and Women's Hospital, Boston, MA, Harvard Medical School Radiation Oncology Program, Boston, MA, Dana-Farber Cancer Institute/ Brigham and Women's Hospital, Boston, MA, Dana-Farber Cancer Institute/ Brigham and Women’s Hospital/ Harvard Medical School, Boston, MA, Dana-Farber Cancer Institute, Brookline, MA, Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, UT MD Anderson Cancer Center, Houston, TX, Memorial Sloan Kettering Cancer Center, New York, NY, University of California San Francisco, San Francisco, CA, Brigham and Women's Hospital/ Dana-Farber Cancer Institute, Boston, MA

Research Funding

Other Foundation

Background: While the addition of androgen deprivation therapy (ADT) to external beam radiotherapy is known to improve overall survival in Gleason 8-10 prostate cancer, it has been hypothesized that Gleason 9-10 disease, which is less differentiated than Gleason 8 disease, may be less sensitive to ADT. To investigate this idea, we examined the association between ADT and overall survival for Gleason 8 versus Gleason 9-10 prostate cancer. Methods: We identified 20,139 men in the National Cancer Database diagnosed with localized or locally advanced, Gleason 8-10 prostate cancer from 2004 through 2011 who received external beam radiotherapy. Patients with clinical evidence of nodal or metastatic disease were excluded. Cox proportional hazards regression was used to examine the association between ADT and overall survival. Results: Median follow-up was 4.0 years. 78.2% (9,509) of the 12,160 men with Gleason 8 disease and 86.6% (6,908) of the 7,979 men with Gleason 9-10 disease received ADT. On multivariable analysis, ADT was associated with a significant improvement in overall survival for Gleason 8 patients (adjusted hazard ratio 0.79, 95% confidence interval 0.71-0.88, P< 0.001) but not Gleason 9-10 patients (adjusted hazard ratio 0.96, 95% confidence interval 0.83-1.10, P= 0.532), with a significant interaction (Pinteraction= 0.020). When considering Gleason 9-10 patients separately as Gleason 9 and Gleason 10, a higher Gleason score correlated with an increased adjusted hazard ratio for the association between ADT and overall survival (Pinteraction= 0.012). Conclusions: In contrast to the significant survival advantage of ADT for Gleason 8 disease, our results strongly suggest that Gleason 9-10 disease may be less sensitive to ADT and that a higher Gleason score predicts lesser sensitivity. Consideration should be given to treatment intensification for Gleason 9-10 patients through enrollment in clinical trials or potentially adding novel antiandrogens or docetaxel, which have shown efficacy in both castration-resistant and castration-sensitive settings.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Localized Disease

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 23)

DOI

10.1200/JCO.2018.36.6_suppl.23

Abstract #

23

Poster Bd #

B7

Abstract Disclosures